BriaCell Total Debt To Capitalization from 2010 to 2024

BCTXW Stock  USD 0.51  0.01  2.00%   
BriaCell Therapeutics Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization is likely to outpace its year average in 2024. During the period from 2010 to 2024, BriaCell Therapeutics Total Debt To Capitalization regression line of quarterly data had mean square error of  0.11 and geometric mean of  0.05. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.000522
Current Value
0.000548
Quarterly Volatility
0.41151393
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 35 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of BriaCell Therapeutics Correlation against competitors.

Latest BriaCell Therapeutics' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of BriaCell Therapeutics Corp over the last few years. It is BriaCell Therapeutics' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

BriaCell Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.23
Geometric Mean0.05
Coefficient Of Variation182.23
Mean Deviation0.34
Median0.54
Standard Deviation0.41
Sample Variance0.17
Range1.4232
R-Value(0.63)
Mean Square Error0.11
R-Squared0.40
Significance0.01
Slope(0.06)
Total Sum of Squares2.37

BriaCell Total Debt To Capitalization History

2024 5.48E-4
2023 5.22E-4
2020 4.54E-4
2019 -0.0746
2018 -0.88

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.